Enhanced T-Helper-1 Lymphocyte Activation Patterns in Acute Coronary Syndromes  by Methe, Heiko et al.
E
A
H
E
M
C
i
m
r
i
a
s
i
(
d
(
C
s
1
M
S
t
e
D
g
2
Journal of the American College of Cardiology Vol. 45, No. 12, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
PAcute Coronary Syndromes
nhanced T-Helper-1 Lymphocyte
ctivation Patterns in Acute Coronary Syndromes
eiko Methe, MD,*† Stefan Brunner,* Daniela Wiegand,* Michael Nabauer, MD,* Joerg Koglin, MD,*
lazer R. Edelman, MD, PHD†
unich, Germany; and Boston, Massachusetts
OBJECTIVES We sought to determine whether different stages of coronary artery disease (CAD) are
associated with distinct differentiation patterns of activated T cells.
BACKGROUND Atherosclerosis is an inflammatory disease. However, little is known about specific inflam-
matory cell activation in atherosclerosis, for example, the T-helper (Th)1/Th2-balance.
METHODS We studied 18 patients with stable angina (SA), 28 patients with acute coronary syndrome
(ACS) (16 with unstable angina pectoris and 12 with ST-segment elevation myocardial
infarction), 19 patients with unheralded myocardial infarction (UH), and 16 control patients.
Cytokine patterns and transcription factor signaling pathways of circulating T cells were
characterized using reverse transcription polymerase chain reaction and flow cytometry.
RESULTS Although interferon (IFN)-/CD3 T cells were 2-fold greater in patients with SA or
UH than in control subjects, there was a massive expansion of Th1 cells in patients with ACS
(p  0.001). This increase was paralleled by significantly increased mRNA transcript levels
for signal-transducer-and-activator-4 (ACS 1.17  0.14 relative units [RU]; control patients
0.44 0.09 RU; SA 0.67 0.12 RU; UH 0.61 0.17 RU), interleukin-2 (ACS 1.55 0.51
RU; control patients 0.21 0.09 RU; SA 0.54 0.18 RU; UH 0.45 0.16 RU), and IFN-
in ACS (1.27  0.39 RU; control patients 0.35  0.09 RU; SA 0.58  0.11 RU; UH
0.53 0.24 RU; p 0.002). Th2 and Th0 cells were not different across patient subsets. The
burden of CAD was identical between SA (1.4  0.2 diseased vessels, 68  13% diameter
stenosis) and ACS (1.4  0.2 diseased vessels, 64  17% diameter stenosis) but significantly
greater in patients with UH (2.5  0.5 diseased vessels, 95  7% diameter stenosis; p  0.05).
CONCLUSIONS Patients with UH have a greater burden of obstructive CAD than SA but no greater T-cell
activation. Patients with ACS have the same extent of CAD than SA but significantly greater
activation of Th1 cells that may contribute to the increasing instability. Differences in
circulating Th1 cells might indicate different pathogenic components, leading to ACS and
UH. (J Am Coll Cardiol 2005;45:1939–45) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.040Cardiology Foundation
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poronary artery disease (CAD) can be considered as an
nterplay between luminal obstruction and intramural inflam-
ation (1). The former may lead to diminished fractional flow
eserve, supply-demand mismatch, myocardial ischemia, and
nfarction. Inflammation can induce a cascade of events that
mplify immune cell infiltration, platelet activation and adhe-
ion, plaque rupture, and intermittent arterial occlusion, lead-
ng to unstable angina pectoris (UA) or myocardial infarction
2–6). T cells in particular exert proatherogenic and plaque-
estabilizing influences and are present in human atheroma
7,8). However, the activation of inflammatory pathways in
AD is not confined to the coronary lesions but includes
timulation of circulating monocytes and lymphocytes (6,9–
1). On activation, T lymphocytes differentiate into T-helper
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005, accepted March 10, 2005.Th)1 and Th2 subsets, characterized by differences in cytokine
epertoire, adhesion mechanisms, effector function profile, and
ocal immune response. Th1 cells express a distinct cytokine
rofile, including interferon (IFN)-, tumor necrosis factor-,
nd interleukin (IL)-2, whereas Th2 cells primarily secrete
L-4 and IL-10 (12–14). Factors in the signal-transducer-and-
ctivator-of-transcription (STAT) protein family regulate Th1
nd Th2 cell differentiation. It has been hypothesized that
TAT4 controls IL-12–mediated Th1 differentiation, whereas
TAT6 controls IL-4–initiated Th2 development (15–18).
Lesions in patients across the spectrum of clinical coro-
ary syndromes possess distinct patterns of occlusion, in-
ammatory cell infiltration, and the presence of immune
ediators. However, the distinction among patients symp-
omatic with stable angina pectoris (SA), acute coronary
yndrome (ACS), those who progress to myocardial infarc-
ions (i.e., ST-segment elevation myocardial infarction
STEMI]), and those whose infarctions are entirely asymp-
omatic and unheralded (UH) remains unclear. Previous
eports have demonstrated different immune activation
atterns between patients with ACS and those with UH
2,10,19), although differences in T-cell activation patterns
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Th1-Mediated Immune Response in ACS June 21, 2005:1939–45etween these two entities have not been demonstrated.
herefore, we determined activation patterns of circulating
cells in patients with SA and ACS and compared them
ith circulating cells in patients with UH and control
atients without evidence of CAD.
ETHODS
tudy patients. This investigation was performed with
pproval by the ethics committee of the Ludwig-
aximilians-University, Munich, Germany. Informed con-
ent was obtained from all subjects. Sixty-five of 119
onsecutive patients admitted to our hospital with a diag-
Abbreviations and Acronyms
ACS  acute coronary syndrome
CAD  coronary artery disease
CK  creatine kinase
CRP  C-reactive protein
FACS  fluorescence-activated cell sorter
IFN  interferon
IL  interleukin
PBS  phosphate-buffered saline
SA  stable angina pectoris
STAT  signal transducer and activator of transcription
STEMI  ST-segment elevation myocardial infarction
Th  T-helper
UA  unstable angina pectoris
UH  unheralded myocardial infarction
able 1. Demographic Characteristics and Biologic Parameters o
Control
(n  16)
S
(n 
ge, yrs 56  11 66
en 8
isk factors
Hypertension — 12 (6
Smoking — 8 (4
Cholesterol, mg/dl 181  27 179
LDL-cholesterol, mg/dl 120  30 132
HDL-cholesterol, mg/dl 45  3 43
Lpa, mg/dl 30  25 24
Glucose, mg/dl 109  9 114
aboratory parameters on admission
CRP, mg/dl 0.1 (0–0.3) 0.2 (0
White blood count, U/I 7.1  0.3 7.2
Lymphocytes, % 32  3.5 38
CK, U/l 35 (14–51) 33 (2
Troponin I, ng/ml n.d. n
xtension of coronary artery disease
Number of diseased vessels — 1.4
% diameter stenosis — 68
edication on admission
Beta-blockers — 12 (6
Aspirin — 16 (8
ACE inhibitors — 8 (4
Lipid-lowering drugs — 14 (7
alues are expressed as mean  SD, median (range), or number (percentage). *p 
ACE  angiotensin-converting enzyme; CK  creatine kinase; CRP  C-reacipoprotein (a); n.d.  not detectable; SA  stable angina pectoris; STEMI  ST-segment
yocardial infarction.osis of CAD were included into the study. Blood samples
ere obtained from all patients in the recumbent position
ith a 21-gauge needle via antecubital venepuncture as soon
s possible after admission. Concentrations of C-reactive
rotein (CRP), white blood cell count, cholesterol, glucose,
roponin-I, and creatine kinase (CK) were measured ac-
ording to routine protocols.
Patients were grouped by presentation (Table 1). A total
f 18 patients had clinical evidence of Canadian Cardiovas-
ular Society class II and III SA (group I) and at least one
oronary artery stenosis detected at angiography (50%
iameter stenosis). A total of 28 patients were admitted to
he coronary care unit of the University Hospital Grosshad-
rn, Munich, Germany, with a diagnosis of ACS and onset
f ischemic chest pain at rest within the preceding 6 h. A
otal of 16 of these patients (group II) fell into Braunwald
lass II or III, that is, exhibiting transient ST-segment
epression and/or T-wave inversion but no evidence of
yocardial infarction by ST-segment elevation or rise in
K or CK-myocardial band (34 U/l; range, 16 to 53 U/l).
roponin I was detected in five of the patients with UA,
lbeit at levels 10.5 ng/ml (6.9; range, 0.9 to 10.5 ng/ml).
he remaining 12 patients with ACS had STEMI (group
II), with elevated levels of CK (394 U/l; range, 297 to 521
/l), CK-myocardial band mass and troponin I (87 ng/ml;
ange, 34 to 123 ng/ml). A total of 19 patients who
resented within 6 h of the onset of the first prolonged chest
ain with ST-segment elevation and increases in CK (392
ients and Control Subjects
UA
(n  16)
STEMI
(n  12)
UH
(n  19)
72  10 65  14 62  13
9 6 10
10 (63) 8 (67) 12 (63)
8 (50) 5 (42) 8 (42)
183  27 192  23 194  36
127  29 129  34 142  24
41  8 40  9 37  7
35  46 35  29 37  31
113  12 118  19 116  13
1.0 (0.3–3.6) 0.9 (0.1–4.5) 0.7 (0.1–2.5)
7.4  1.0 7.3  2.2 7.5  3.8
33  4.0 33  1.9 35  1.5
34 (16–53) 394 (297–521)* 392 (213–629)*
6.9 (0.9–10.5) 87 (34–123)† 79 (14–187)†
1.3  0.2 1.4  0.2 2.5  0.5*
66  16 62  19 95  7‡
11 (69) 9 (75) 14 (74)
12 (75) 10 (83) 15 (79)
8 (50) 7 (58) 10 (53)
12 (75) 9 (75) 14 (74)
†p  0.05 UA vs. STEMI and UH; ‡p  0.05.
rotein; HDL  high-density lipoprotein; LDL  low-density lipoprotein; Lpa f Pat
A
18)
 13
9
7)
4)
 22
 36
 8
 38
 8
–0.5)
 0.5
 2.5
0–43)
.d.
 0.2
 13
7)
9)
4)
8)
0.01;
tive pelevation myocardial infarction; UA  unstable angina pectoris; UH  unheralded
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June 21, 2005:1939–45 Th1-Mediated Immune Response in ACS/l; range, 213 to 629 U/l) and troponin I (79 ng/ml; range,
4 to 187 ng/ml) with no history of ischemic heart disease
r chronic SA and no acute events or worsening of symp-
oms in the last six months were identified as group IV
patients with UH). Identification of STEMI and UH
ollowed the recent consensus document of the American
eart Association and the American College of Cardiology
20). All patients underwent coronary angiography during
ospitalization.
Exclusion criteria for this study included previous myo-
ardial infarction within six months (15 patients), admission
ore than 6 h from onset of symptoms (18 patients),
nflammatory conditions likely to be associated with an
cute-phase response (8 patients), autoimmune disease (4
atients), and neoplastic disease (9 patients). None of the
ncluded patients had advanced liver disease, renal failure, or
alvular heart disease. Group V included 16 healthy volun-
eers with no clinical signs of CAD and who were without
oronary risk factors. All of these control patients had
ormal electrocardiography and echocardiograms and no
vidence of atherosclerosis by carotid artery sonography.
solation of CD4-lymphocytes, mRNA isolation, and
emiquantitative reverse transcription polymerase chain
eaction (RT-PCR). Isolation of mononuclear cells from
eparinized blood was performed by Ficoll density gradient
entrifugation (Becton Dickinson, Heidelberg, Germany).
fter isolation, mononuclear cells were washed twice in
hosphate-buffered saline (PBS) and re-suspended at 107
ells/ml in PBS. CD4 T lymphocytes were isolated using
ACS-CD4 beads following the manufacturer’s instruc-
ions (Miltenyi Biotec, Bergisch Gladbach, Germany).
ynabeads Oligo(dT)25 were used to isolate mRNA
Dynal, Oslo, Norway). First-strand cDNA synthesis was
erformed using oligo(dT)12-18 and a superscript preampli-
cation kit (Invitrogen, Karlsruhe, Germany). Primers for
CR were designed with MacVector 5.0 (Oxford Molecular
cientific, Sunnyvale, California), and logarithmic amplifi-
ation ranges established as described previously (21). For
ach individual primer pair, specific annealing temperature
nd cycle number were optimized by serial annealing stud-
es, PCR cycle studies, and cDNA dilution studies (Table
). Duplicate samples were amplified with AmpliTaq Gold
NA polymerase (Applied Biosystems, Darmstadt, Ger-
any). After electrophoresis, agarose gels were incubated
or 20 min at room temperature with SYBRGold (Molec-
lar Probes, Eugene, Oregon). Fluorescence was induced by
V transillumination (300 nm) and samples quantified
sing a BioRad FluorS-Multiimager and Quantity-One
oftware (BioRad, Munich, Germany) for densitometric
nalysis. A negative control and an internal standard were
un on each gel. Transcript levels were normalized to
lyseraldehyde-3-phosphate dehydrogenase and reported as
ean  SD.
ntracellular staining and flow cytometry. Heparinized
hole blood was diluted (1:1) with RPMI1640 and stimu-ated with 1 g/ml phorbol 12-myristate 13-acetate and q0 g/ml ionomycin in 500 g/ml of Brefeldin A (all
igma-Aldrich, Poole, United Kingdom). Samples were
ncubated for 4 h at 37°C/5% CO2, which are conditions
hat maximally activate T cells and accumulate intracellular
ytokine (22). Stimulated and unstimulated (Brefeldin A
lone) samples were then stained with CD3-PerCP anti-
ody (mouse IgG1 anti-human, clone SK7, Pharmingen,
an Jose, California) at room temperature for 15 min.
rythrocytes were lysed with fluorescence-activated cell
orter (FACS) lysis buffer (Becton Dickinson Immunocy-
ometry Systems [BDIS], San Jose, California). Lympho-
ytes were washed in PBS 0.5% bovine serum albumin and
.1% sodium azide and then incubated in FACS permeabil-
zation solution (BDIS) for 10 min. Permeabilized cells
ere washed twice and stained with IFN--fluorescein
sothiocyanate (mouse IgG2b anti-human, clone 25723.11)
nd IL-4-phycoerythrin (mouse IgG1 anti-human, clone
010.211) antibodies (or IgG2b fluorescein isothiocyanate/
gG1 phycoerythrin isotype-control, all obtained from
harmingen) for 30 min at room temperature. Finally,
amples were washed once and then resuspended in 1%
araformaldehyde/PBS before acquisition on a FACScan
BDIS). At a threshold set to exclude non-CD3 cells,
0,000 events were collected by Cellquest software (BDIS).
he population of CD3 T lymphocytes was gated by
orward and side-scatter characteristics. Isotype controls
nabled correct compensation and confirmed antibody spec-
ficity. Unstimulated samples set the quadrants for two-
imensional dot plot analysis. Results were expressed as
ercentage of all CD3 T-cell subtypes staining positive for
he specific cytokine. Intra-assay variability was assessed by
ndependently activating, staining, and analyzing two ali-
able 2. Primer Sequences, Sequence Accession Numbers,
nnealing Temperatures, and Cycle Numbers
APDH (M33197), 68°C/25 cycles
Sense AAGGTCGGAGTCAACGGATTTGG
Antisense AGGCATTGCTGATGATCTTGAGGC
FN- (M29383), 59°C/33 cycles
Sense CATCCAAGTGATGGCTGAACTGTCG
Antisense AAGCACTGGCTCAGATTGCAGGC
L-2 (V00564), 62°C/36 cycles
Sense GCATTGCACTAAGTCTTGCACTTG
Antisense AGCACTTCCTCCAGAGGTTTGAG
L-4 (M13982), 66°C/34 cycles
Sense CGTAACAGACATCTTTGCTGCCTCC
Antisense TCTTTGCTGCCTCAAGAACACAAC
L-10 (M57627), 68°C/32 cycles
Sense AACCAAGACCCAGACATCAAGGCG
Antisense AAGGCATTCTTCACCTGCTCCACG
TAT4 (L78440), 66°C/31 cycles
Sense GTGGTTGAGCGACAGCCATGTATG
Antisense TGGATGCCCAAGCATTAGGTAACTG
TAT6 (U16031), 66°C/28 cycles
Sense GCAGTTCAACAAGGAGATCCTGCTG
Antisense TTTCCACGGTCATCTTGATGGTAGC
APDH  glyseraldehyde-3-phosphate dehydrogenase; IFN  interferon; IL 
nterleukin; STAT  signal transducer and activator of transcription.uots of the same blood sample.
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Th1-Mediated Immune Response in ACS June 21, 2005:1939–45tatistical analysis. Statistical analysis was performed with
MP statistical software (SAS Institute Inc., Cary, North
arolina). The Shapiro-Wilk test was used to determine
hether values followed a normal distribution. Because
RP, low-density lipoprotein cholesterol, troponin I, and
K values did not follow a normal distribution, compari-
ons between groups were conducted using the Wilcoxon
est for two and the Kruskal-Wallis test for more than two
roups. The remaining continuous variables were compared
sing the Student t tests for two and one-way analysis of
ariance for more than two groups. Categorical variables
ere compared by the chi-square test. Significant values
ere not adjusted for multiple comparisons. C-reactive
rotein, low-density lipoprotein cholesterol, troponin I, and
K values are expressed as median and range, the remaining
ariables are expressed as mean  standard deviation or
umber (%). A Spearman correlation determined relations
etween mRNA transcript levels and frequencies of IFN-
–producing T cells. A p value of 0.05 was considered
tatistically significant.
ESULTS
atient characteristics. There were no significant differ-
nces in age, gender, lipid or blood glucose, frequency of
moking, or use of medications in patients with SA, ACS,
r UH. Patients with ACS or UH were treated with
tandard antianginal medications, intravenous heparin, as-
irin, and nitroglycerin. Patients with UH had a greater
xtent of CAD (2.5  0.5 diseased vessels; p  0.01) and
igher degree of diameter stenosis (95 7%; p 0.05) than
hose with SA (1.4  0.2 diseased vessels; 68  13%), UA
1.3  0.2 diseased vessels; 66  16%), or STEMI (1.4 
.2 diseased vessels; 62  19%) (Table 1, Fig. 1).
ssessment of frequencies of IFN-– and IL-4–
roducing T cells. Patients with SA and UH showed
aised levels of activated T cells compared with control
atients; 1.9- and 1.7-fold greater than control values (Figs.
and 3), although only the patients with SA reached
tatistical significance (p  0.01). Clinical instability of
igure 1. Frequency of interferon (IFN)-/CD3 T cells in relationship
o diameter of stenosis and to markers of myocardial damage. Results are
hown as mean values  SD or as median and range. Closed squares 
FN-/CD3 cells; closed circles  diameter stensosis (DS); open
iamonds  creatine kinase (CK); open trianges  troponin I. SA 
table angina pectoris; STEMI  ST-segment elevation myocardial
nfarction; UA  unstable angina pectoris; UH  unheralded myocardial
nfarction.
a
Soronary syndromes was associated with increased expan-
ion of circulating IFN-/CD3 lymphocytes in patients
resenting with ACS (4.6-fold increase to controls, 2.4-fold
o SA, and 2.7-fold to UH; p  0.0002 vs. controls, p 
.001 vs. SA and UH) (Figs. 2 and 3). There were no
ignificant differences between patients with UA and pa-
ients with STEMI (p  0.68) (Fig. 3) or between patients
ith high and low troponin levels (p  0.53). In contrast,
here were no significant differences in the frequencies of
eripheral circulating Th2 cells (IL4/CD3 population)
r Th0 cells (IL4/IFN-/CD3 population) between
he groups (Fig. 2, Table 3).
h0, Th1, and Th2 cytokine and STAT4 and STAT6
ranscript levels. mRNA expression by RT-PCR followed
rotein detection by FACS analysis. Transcript levels for
he Th1 signal transducer STAT4 were significantly higher
n patients with UA (1.14  0.11 relative units [RU]; p 
igure 2. Representative plots from a control patient (A) and a patient
ith stable angina pectoris (B), acute coronary syndrome (C), and
nheralded myocardial infarction (D). Ten thousand CD3 cells were
ated and analyzed for expression of interferon (IFN)- or interleukin
IL)-4. Each dot represents a CD3 T cell. Numbers represent the
ercentage of cells in the quadrants, respectively.
igure 3. Peripheral blood mononuclear cells from control patients and
rom patients with stable angina pectoris (SA), unstable angina pectoris
UA), ST-segment elevation myocardial infarction (STEMI), and unher-
lded myocardial infarction (UH) were immunostained with antibodies
gainst CD3 and interferon (IFN)- and analyzed by flow cytometry.
ymbols  individual data; dashed lines  mean values  SD.
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June 21, 2005:1939–45 Th1-Mediated Immune Response in ACS.002) and STEMI (1.2  0.18 RU; p  0.002) than in all
ther groups (control, 0.44  0.09 RU; SA, 0.67  0.12
U; UH, 0.61  0.17 RU). Patients with SA and UH had
ncreased mRNA levels of STAT4 compared with controls,
ut only patients with SA reached statistical significance
p  0.05) (Fig. 4). Similar results were observed for the
h1 marker cytokines IL-2 and IFN-, with increased
RNA transcript levels in the ACS group compared with
A, UH, and control patients (p 0.002). Patients with SA
nd UH showed increased IL-2 and IFN- levels compared
ith control patients, although only patients with SA
eached statistical significance (p  0.05) (Fig. 4). There
ere no significant differences in relative transcript levels for
he Th2 signal transducer STAT6 or for the Th2 marker
ytokines IL-4 and IL-10 in any of the patient groups (Fig.
). A strong correlation was noted between the frequency of
eripheral circulating IFN-/CD3 lymphocytes and
RNA transcript levels of IFN- (r  0.68; p  0.002) and
TAT4 (r 0.88; p 0.001) across all patient groups (Fig. 5).
ISCUSSION
vidence is accumulating that the destabilization of athero-
clerotic disease is associated with a systemic immune
ctivation (3–6,10). However, factors responsible for the
ransition from stable to unstable coronary disease remain
ncompletely understood. Coronary lesions infiltrated with
mmune cells, including macrophages and T lymphocytes,
re thought to be most unstable. However, it is unclear
hether inflammation precedes and perhaps triggers plaque
upture, platelet activation, coronary occlusion, and resul-
ant myocyte ischemia/necrosis or is a side effect of these
athologic processes. In this regard, the current investiga-
ion suggests two important novel observations. First, al-
hough patients with stable CAD and ACS have the same
xtent of CAD, patients with ACS exhibit an expansion of
eripheral circulating activated CD3 cells, phenotypically
haracterized as Th1 lymphocytes. More importantly, in-
reased activation of Th1 cells in these patients is observed
efore myocardial damage and remains elevated in patients
ith STEMI. Second, patients presenting with entirely UH
ave a greater burden of atherosclerotic disease and a high
rade of coronary artery occlusion, but their T-cell activa-
ion levels comparable with patients with SA.
The results of our study are consistent with previous
ndings that an inflammatory stimulus, in addition to the
able 3. No Expansion of Th2 or Th0 Cells in Patients With D
Control
(n  16) (n
h2 cells (IL-4/CD3) 0.9  0.8% 1.7
h0 cells (IL-4/IFN-/CD3) 0.9  0.7% 1.2
ata are presented as mean percentage  SD.
IFN  interferon; IL  interleukin; SA  stable angina pectoris; STEMI  ST
H  unheralded myocardial infarction.acroscopic obstructive disease, may be present throughout
m
migure 4. (A) Representative examples of reverse transcription polymerase
hain reaction amplification products of each group. 1, control; 2, stable
ngina; 3, unstable angina; 4, ST-segment elevation myocardial infarction;
, unheralded myocardial infarction. (B) Reverse transcription polymerase
hain reaction amplification was normalized against glyseraldehyde-3-
hosphate dehydrogenase and is presented as mean corrected transcript
evels  SD in relative units (RU) of duplicate analysis of all patients in
ach group. *p  0.002 vs. control, SA, and UH; †p  0.05 vs. control
atients. GAPDH  glyceraldehyde-3-phosphate dehydrogenase; IFN 
nterferon; IL  interleukin; SA  stable angina pectoris; STAT  signal
ransducer and activator of transcription; STEMI  ST-segment elevationifferent Stages of Atherosclerosis
SA
 18)
UA
(n  16)
STEMI
(n  12)
UH
(n  19)
 1.9% 0.8  1.2% 1.1  0.9% 1.1  1.5%
 1.2% 1.0  1.0% 0.9  0.8% 1.4  1.9%
-segment elevation myocardial infarction; Th  T-helper; UA  unstable angina pectoris;yocardial infarction; UA  unstable angina pectoris; UH  unheralded
yocardial infarction.
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Th1-Mediated Immune Response in ACS June 21, 2005:1939–45he atherosclerotic disease process (23) and that a time-
ependent activation of the immune system can be found in
atients with UA (2,10). The existence of an acute inflam-
atory state in patients with UA is supported by other
linical studies demonstrating elevated levels of unspecific
arkers of inflammation, ILs and IFN-, as well as activa-
ion of circulating T lymphocytes and monocytes (3–
,10,24). Several in vivo animal studies have stressed the
mportance of a Th1-driven immune response in athero-
clerosis. The transfer of CD4 T cells from atherosclerotic
onors to immunodeficient mice aggravates the atheroscle-
otic process. In turn, T-cell transfer is accompanied by an
levation of systemic IFN- levels (25). Furthermore, lesion
evelopment in mice prone to atherosclerosis can be inhib-
ted by the pharmacologic blockade of Th1 or through
L-10 stimulation of Th2 differentiation, which counteracts
h1 differentiation (26,27). Moreover, data derived from
atients with coronary heart disease have revealed that
eripheral circulating T cells appear to change around the
ime of clinically manifest atherosclerotic disease
7,11,28,29) and that patients with spastic angina showed a
reference toward a Th1 response (3,30).
To our knowledge, there are no reports on the relation
etween the signaling factors of the two T-cell subset
rograms (STAT4 and STAT6) and different stages of
AD. Our findings could be further proof that Th1 cells are
ctivated throughout the evolution of CAD. It was previ-
usly shown that targeted deletion of the transcription
actor STAT4 resulted in attenuated cardiac allograft vas-
ulopathy in transgenic mice (31). Here, we show for the
rst time that SA and ACS are associated with the
p-regulation of STAT4 transcript levels in peripheral
irculating CD4 T cells.
Notably, the extent of Th1 cell activation was significantly
ower in UH patients with myocardial infarction without
ntecedent instability than in patients with ACS. Patients with
H were more likely to have multivessel disease and more
ignificant stenoses of the infarct-related artery than patients
ith ACS. A missing correlation between extent of coronary
igure 5. Spearman correlation of frequencies of circulating interferon (I
ransducer and activator of transcription 4 (B). Area of the density ellipse
ransducer and activator of transcription.rtery stenosis and frequency of IFN-/CD3T cells already Tas been demonstrated (30), and the number of T cells present
n human plaques relates to the overall plaque morphology, i.e.,
ow in more stable fibrous plaques but high in rupture prone
esions. T cells accumulate at the shoulder region of lesions
here the cap is often thinnest, most heavily infiltrated with
nflammatory cells, and most likely to rupture (32). Hence,
-cell activation may not be the driving force in patients with
substantial burden of fixed obstructive disease but is all the
ore essential in destabilization of vulnerable and susceptible
etabolically active plaques. Characteristic histomorphologic
eatures of vulnerable plaques include a high lipid content,
ncreased numbers of inflammatory cells, and extensive neo-
ascularization. T cells facilitate the propagation of the im-
une response via attraction and activation of leukocytes and
acrophages, reduce smooth muscle cell population, and
ontribute to endothelial cell damage, partly because of an
FN-–induced dysregulation of nitric oxide production (33–
5). Activated T cells also inhibit matrix synthesis through the
roduction of IFN- and promote apoptotic processes within
ulnerable plaques (33,36,37). Thus, plaques producing non–
ow-limiting stenosis likely account for more plaque rupture
nd thrombosis than more severe stenosis (38,39).
Increases in inflammatory markers in patients with UA
hen compared with UH have been previously reported
2,10,19). Unlike patients with UH, those with UA exhibit
igher levels of tissue factor expression than patients with
A (9). Furthermore, patients with UA showed higher
evels of CRP, serum amyloid A protein, and IL-6 when
ompared with patients with UH (19,40).
tudy limitations. This study was performed with a small
umber of patients and did not accumulate data sequentially
ith time. Moreover, the critical question remains as to
hether Th1 cells are activated by the processes involved in
laque destabilization or whether they cause the destabili-
ation to occur in the first place. Further studies might
xamine the kinetics of T-cell activation to underline the
otion of transitory phenomenon and to determine whether
he patients with UH, in particular, will demonstrate late
/CD3 T cells and mRNA transcript levels of IFN- (A) and signal
sents the 95% confidence interval. RU  relative units; STAT  signalFN)-
repre-cell activation.
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o indexes of myocardial damage supports the idea that
ctivation of cellular immune responses and up-regulation
f immune mediators contribute to plaque instability and
re not simply a consequence of myocardial injury. Our
bservation of T-cell activation in patients with SA brings
urther evidence to the hypothesis that a triggering inflam-
atory stimulus is present throughout the atherosclerotic
isease process (23). Therefore, STAT4-mediated immune
rocesses and Th1 subtypes likely affect the evolution of
CS. In line with other studies, our findings suggest that
he two clinical presentations of UA preinfarction and UH
ight be associated with different pathogenetic components
f acute coronary occlusion.
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